These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 25074643)

  • 1. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
    Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
    Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia.
    Piga A; Fracchia S; Lai ME; Cappellini MD; Hirschberg R; Habr D; Wegener A; Bouillaud E; Forni GL
    Br J Haematol; 2015 Mar; 168(6):882-90. PubMed ID: 25402221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox.
    Naderi M; Sadeghi-Bojd S; Valeshabad AK; Jahantigh A; Alizadeh S; Dorgalaleh A; Tabibian S; Bamedi T
    Pediatr Hematol Oncol; 2013 Nov; 30(8):748-54. PubMed ID: 24134694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
    Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
    Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
    Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
    Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary Functions in Children With Thalassemia Major.
    Ozyoruk D; Misirlioglu ED
    J Pediatr Hematol Oncol; 2015 Nov; 37(8):605-10. PubMed ID: 26422288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
    Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF; Peng CT; Wu KH; Tsai CH
    Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Prossomariti L
    Acta Haematol; 2010; 123(2):117-20. PubMed ID: 20068283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.